.png){kind=icon}
.png){kind=icon}
Return
Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis
.png){kind=icon}
PRE
AI
B
C
A
DOI：10.1016/j.cardfail.2026.06.025.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Obesity is a major risk factor for heart failure with preserved ejection fraction (HFpEF). Incretin-based therapies are associated with a reduction in worsening heart failure (HF) events for patients with HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), although the time to clinical benefit from these therapies is unknown.
Journal
IF:
8.2
Papers:
1.2W
Citations:
7.6K
Organization
Cited Papers